Skip navigation.

Guidelines on Postexposure Prophylaxis for HIV and the use of Co-Trimoxazole Prophylaxis for HIV-Related Infections Among Adults, Adolescents and Children: Recommendations for a Public Health Approach

Publication year: 
2014
Corporate author: 
WHO
Publication details: 
Geneva, WHO, 2014
Abstract:

In this second supplement to the 2013 WHO consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection, recommendations from two guideline development processes are included:
• post-exposure prophylaxis for HIV;
• the use of co-trimoxazole prophylaxis for HIV-related infections among adults, adolescents and children.

These guidelines provide new recommendations and updates to previous recommendations outlined in Chapter 5 (ARV drugs for HIV prevention) and Chapter 8 (Managing common coinfections and comorbidities) of the 2013 consolidated ARV guidelines, and following the similar structure of the 2013 ARV guidelines, these recommendations are organized along the continuum of care.

These guidelines reflect important advances in the use of ARV drugs to prevent HIV with more simplified approaches to postexposure prophylaxis and simplifying the indications on the use of co-trimoxazole to prevent opportunistic infections, bacterial
infections and malaria. Consistent with previous WHO guidelines, these guidelines are based on a public health approach that considers feasibility and effectiveness across a variety of settings. The key principles of availability, affordability, acceptability,
accessibility and quality have been considered in producing these recommendations.

The primary audience for these guidelines is policy-makers and programme managers of HIV and disease control programmes. Health facilities and teaching institutions are also expected to use the guidelines to set up and maintain care services. In addition, the guidelines will be of interest to health professionals who are responsible for providing care to children, adolescents and adults in settings with HIV, primarily in low- and middle-income countries.